Global Generics & Biosimilars Awards 2018 ceremony (5th time), organized by Generics Bulletin, a global leading trade magazine in UK, co-hosted by IQVIA, was held on 9 October 2018 at the Palacio Municipal de Congresos in Madrid, Spain. At the ceremony, Shanghai Henlius Biotech, Inc., (Henlius) was highly recognized and nominated for the Company of the Year, Asia-Pacific and the Biosimilar Initiative of the Year (rituximab injection HLX01).
Being nominated for “Global Generics & Biosimilars Awards 2018” does not only reflect Henlius’ impressive performance in the biotech industry, but also recognize the company’s influence in Asia-Pacific, and even global biopharmaceutical markets. Since established in 2009, Henlius has built a highly productive and integrated monoclonal antibody development and production platform with its R&D footprints in Shanghai, Taipei and California, USA.
In order to realize “Affordable Innovation”, Henlius is dedicated to fulfilling unmet medical needs by providing high quality and affordable antibody-based therapeutics. Apart from strengthening the bio-novel pipeline and combination immuno-oncology therapy,Henlius has also developed a robust biosimilar portfolio with many products currently in clinical stage. Henlius has submitted its first New Drug Application (NDA) of HLX01 to National Medical Products Administration (NMPA, formerly CFDA), making HLX01 potentially the first biosimilar in China.
Following its international strategy of “in China for Global”, Henlius continues researching and developing new products to enrich the product pipeline and portfolio while also speeding up its globalization strategy. Henlius’ second product of HLX02, a trastuzumab biosimilar, is conducting a global multi-center phase 3 trial in mainland China, Ukraine, Poland and the Philippines. HLX02 is also the first Chinese biosimilar product getting clinical trial approvals outside China.
With the vision of becoming the most admired biotech company by providing innovative and affordable medicines for all patients, Henlius will continue leveraging its global synergy and integrated innovation to produce high quality and affordable protein therapeutics in alignment with international quality standards.
About Global Generics & Biosimilars Awards
The Global Generics & Biosimilars Awards reward ‘best practice’ in the two industries, at the same time encouraging improvements in every aspect of the way business is conducted.
Business development initiatives – such as through innovative product development, clever licensing deals or smart legal manoeuvres – are at the heart of the Global Generics & Biosimilars Awards. Equally important will be recognized as the industries’ best executives and leading companies.
Every Award will effectively underscore the efforts made by the global generics and biosimilars industries to make more affordable medicines to benefit more people everywhere.
Shanghai Henlius Biotech, Inc., a joint venture company co-founded by Fosun Pharma and a team of overseas scientists in December 2009, with its R&D footprint in Shanghai, Taipei and California, USA, specializes in the discovery, development, manufacturing and commercialization of high-quality biologics including biosimilar, biobetter and novel monoclonal antibody, to treat tumor and auto-immune disease.
Until now, Henlius has completed IND/CTA filings of 12 products and 1 combination therapy with 20 indications and obtained 26 successful IND/CTA approvals (16 approvals from China; 3 from the United States; 3 from Taiwan; each 1 from the European Union, Ukraine, the Philippines and Australia).